You are here: Industry Insights > AstraZeneca

News List

EU approves AstraZeneca immunotherapy drug for lung cancer expressbpd
September 26, 2018
The green light from the EU had been expected following a positive recommendation from experts at the European Medicines Agency
AstraZeneca’s Lumoxiti secures FDA nod to treat hairy cell leukaemia pharmaceutical-technology
September 21, 2018
AstraZeneca and its research and development arm MedImmune have obtained approval from the US Food and Drug Administration (FDA) for the use of Lumoxiti to treat adults with relapsed or refractory hairy cell leukaemia.
AstraZeneca plots China robot offensive to counter price cuts expressbpd
September 21, 2018
With smart cancer diagnostics and AI systems to improve ambulance pick-ups for patients with chest pain, AstraZeneca aims to move from simply supplying drugs to becoming a broad healthcare provider in China
Trial takes FibroGen’s renal anemia drug closer to EU filing fiercebiotech
September 21, 2018
Roxadustat outperformed placebo in its ability to boost hemoglobin levels
FDA approves AstraZeneca’s Lumoxiti for hairy cell leukaemia (HCL) pharmafile
September 20, 2018
AstraZeneca’s Lumoxiti has been approved for use for the treatment of relapsed or refractory hairy cell leukemia (HCL)in adults who have had at least two prior therapies for the disease.
AstraZeneca to increase presence in China pharmafile
September 20, 2018
The Anglo-Swedish multinational AstraZeneca is moving towards becoming a major healthcare provider in China as part of an effort to expand the overall market...
AZ’ Fasenra shows long-term efficacy in eosinophilic asthma pharmatimes
September 20, 2018
AstraZeneca has unveiled data from a Phase III extension trial highlighting the efficacy of biologic Fasenra as an add-on maintenance treatment...
AstraZeneca, shut out of COPD, touts long-term Fasenra asthma data fiercepharma
September 20, 2018
AstraZeneca struck out in May in trying to expand severe eosinophilic asthma drug Fasenra into COPD. But it does have new long-term data that could bolster the drug in its current indication.
US approves AZ’ hairy cell leukaemia drug pharmatimes
September 18, 2018
AstraZeneca and its biologics R&D arm MedImmune have bagged US approval of Lumoxiti for the treatment of hairy cell leukaemia...
FDA Approves New Kind of Treatment for Hairy Cell Leukemia americanpharmaceuticalreview
September 18, 2018
The U.S. Food and Drug Administration (FDA) approved Lumoxiti (moxetumomab pasudotox-tdfk) injection for intravenous use for the treatment of adult patients...

Previous page 1 2 3 4 5 6 7 8 9 10 ... 80 81 Next page